DALLAS--(BUSINESS WIRE)--Nov. 14, 2005--Kos Pharmaceuticals, Inc. (Nasdaq: KOSP): Reverse-D4F, a Novel Apo A-I Mimetic Peptide, Showed 46% Reduction in Atherosclerotic Lesion Area in a Preclinical Animal Model. The Data Indicate that Reverse-D4F is at Least as Effective as D-4F in Reducing the Progression of Atherosclerosis at Early Stages of Lesion Formation in Apo E-null Mice. Data Represents Early Productivity in the Area of Potential New Chemical Entity Design Through Kos’ Sponsored Research Agreement With Arisaph.
